NKG2A, a New Kid on the Immune Checkpoint Block
- PMID: 30550781
- DOI: 10.1016/j.cell.2018.11.048
NKG2A, a New Kid on the Immune Checkpoint Block
Abstract
One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8+ T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29. Cell. 2018. PMID: 30503208 Free PMC article.
-
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
